Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review.

ABSTRACT:

Background

There is currently at least 1 biologic (adalimumab) approved in North America for treatment of Hidradenitis Suppurativa in the pediatric population. However, no reviews or clinical trials have specifically analyzed the effectiveness and safety data of biologic use in this population. The objective of this systematic review is to identify and summarize the outcomes of biologic therapy in pediatric patients with HS.

Methods

MEDLINE and EMBASE databases were used to conduct the search on Sept 18, 2020.

Results

The 15 included studies consisted of 26 patients, with the mean age of 15 ± 2.3 years. Females accounted for 53.8% (n = 14/26) of cases. The mean duration of HS prior to biologic initiation was 3.5 ± 2.9 years, with the majority having Hurley Stag

SUBMITTER: Sachdeva M 

PROVIDER: S-EPMC8978460 | biostudies-literature | 2022 Mar-Apr

REPOSITORIES: biostudies-literature